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Myeloperoxidase (MPO) is a lysosomal enzyme that may be
involved in oxidative stress–mediated kidney injury. Using a
two-step approach, we measured the association of four
polymorphisms across the length of the MPO gene with
systemic markers of oxidative stress: plasma MPO and urinary
15-F2t-isoprostane levels. Adverse outcomes were measured
in a primary cohort of 262 adults hospitalized with acute
kidney injury, and a secondary cohort of 277 adults
undergoing cardiac surgery with cardiopulmonary bypass
and at risk for postoperative acute kidney injury. Dominant
and haplotype multivariable logistic regression analyses
found a genotype–phenotype association in the primary
cohort between rs2243828, rs7208693, rs2071409, and
rs2759 MPO polymorphisms and both markers of oxidative
stress. In adjusted analyses, all four polymorphic allele
groups had 2–3-fold higher odds for composite outcomes of
dialysis or in-hospital death or a composite of dialysis,
assisted mechanical ventilation, or in-hospital death. The
MPO T-G-A-T haplotype copy-number was associated with
lower plasma MPO levels and lower adjusted odds for
the composite outcomes. Significant but less consistent
associations were found in the secondary cohort. In
summary, our two-step genetic association study identified
several polymorphisms spanning the entire MPO gene locus
and a common haplotype marker for patients at risk for acute
kidney injury.
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Acute kidney injury (AKI) is a common occurrence in the
hospital setting, and confers an increased risk of mortality, as
well as heightened resource consumption, including prolonged
hospital stay and increased costs.1,2 Although many factors
have been identified as predictors of development and
evolution of AKI,3–9 there remains significant unexplained
variability in the prediction of adverse kidney-related
outcomes.10,11 In recent years, polymorphisms in several
candidate genes have been explored as determinants of disease
severity and adverse outcomes in patients with AKI.12–19
Myeloperoxidase (MPO) is a heme-containing enzyme
belonging to the XPO subfamily of peroxidases. It is
abundant in neutrophils and catalyzes the hydrogen perox-
ide–dependent formation of hypochlorous acid, a potent
oxidant.20 Neutrophils store MPO in cytoplasmic azurophilic
granules.21 Upon cellular activation and degranulation, MPO
is delivered into phagolysosomes where it is required for
killing of phagocytosed bacteria.22 Activated neutrophils also
release granule contents in the extracellular space. Elevated
plasma MPO levels have been associated with a variety of
clinical conditions, including ischemia-reperfusion injury,
acute pancreatitis, vasculitis, atherosclerosis, cancer, and
neuro-degenerative disorders.23–25
The human MPO gene is located on chromosome
17q23.1.26 Several polymorphisms have been described in
the MPO gene locus, some of which have been linked to
systemic markers of oxidative stress in patients with chronic
kidney disease.27,28 Genetic variation in the expression of this
key enzyme might thus account for the inter-individual
variability observed in the severity and outcome of AKI.29 In
the present report, we first examine the association of four
polymorphisms and haplotypes in the MPO gene locus with
systemic markers of oxidative stress, measures of disease
severity, and adverse clinical outcomes in hospitalized adults
with an established diagnosis of AKI (‘primary cohort’).
Next, we examine the association of the same polymorphisms
with adverse outcomes in a second cohort of adults at risk for
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AKI undergoing cardiac surgery with cardiopulmonary
bypass (CPB; ‘secondary cohort’).
RESULTS
Characteristics of participants in the primary and secondary
cohorts
In the primary cohort, between November 2003 and
February 2010, a total of 264 participants were enrolled of
whom two were excluded owing to study ineligibility and
lack of genomic DNA sampling. The present analysis includes
262 participants who underwent genotyping analyses. At
enrollment, mean age was 66 years, 91% were white, and 53%
were men. Mean Acute Physiology and Chronic Health
Evaluation (APACHE) II score was 20, and 73% were in the
intensive care unit. In all, 137 (53%) subjects had stage 3
AKI, as defined by the AKI network criteria. Twenty-four
percent required mechanical ventilation, 39% required
dialysis, 22% died in hospital, and 47% experienced the
composite outcome of dialysis requirement or in-hospital
death.
In the secondary cohort, between January 2004 year and
August 2011, a total of 277 participants were enrolled. In
brief, mean age was 68 years, 95% were white, 72% were men,
37% had a history of heart failure, and preoperative mean
serum creatinine was 1.1mg/dl. Thirty-one percent under-
went elective cardiac surgery, with 51% requiring valve
replacement. Mean aortic cross-clamp and CPB perfusion
time were 91 and 118min, respectively. On postoperative day
1, mean APACHE II score was 13, initial median mechanical
ventilation was 9 h, and stage 2 or 3 AKI developed in seven
(2.5%) subjects.
Characteristics of the primary and secondary cohorts
stratified by MPO gene polymorphisms
In both the primary and secondary cohorts, tests for
Hardy–Weinberg equilibrium showed no deviation from
expected frequencies (Table 1). All the four MPO gene
polymorphisms had minor allele frequencies of 45%.
The characteristics of the primary cohort stratified by the
four MPO gene polymorphisms are shown in Table 2. In
brief, demographic characteristics, comorbidities, and disease
severity measures did not significantly differ across geno-
types, with a few notable exceptions. The MPO rs2243828
minor C-allele (TC/CC genotype) group had a higher mean
APACHE II score (P¼ 0.002), and lower mean urine output
(P¼ 0.05) compared with the TT genotype group; the MPO
rs7208693 minor T-allele group (GT/TT genotype) had a
higher prevalence of cirrhosis (P¼ 0.02) and more advanced
stages of AKI (P¼ 0.02), and a higher mean APACHE II score
(Po0.001) compared with the GG genotype group; the MPO
rs2071409 minor C-allele group (AC/CC genotype) had a
higher prevalence of sepsis (P¼ 0.01) and lower mean urine
output (P¼ 0.02) compared with the AA genotype group; the
MPO rs2759 minor C-allele group (TC/CC genotype) had a
lower prevalence of diabetes mellitus (P¼ 0.02), a higher
prevalence of cirrhosis (P¼ 0.02), sepsis (P¼ 0.03), and shock
(P¼ 0.04), and a higher mean APACHE II score (Po0.001)
and lower mean urine output (Po0.001) compared with the
TT genotype group.
Similarly, the characteristics of the secondary cohort
stratified by the four MPO gene polymorphisms are shown
in Table 3. In brief, the preoperative, operative, and
postoperative variables did not significantly differ across
genotypes, with a few exceptions. The MPO rs7208693 minor
T-allele group (GT/TT genotype) had a higher prevalence of
planned elective surgery (P¼ 0.03) and valve replacement
(P¼ 0.04), a prolonged mean aortic cross-clamp time
(P¼ 0.01) and CPB perfusion time (Po0.001), and a higher
postoperative day-1 mean APACHE II score (Po0.001)
compared with the GG genotype group; similarly, the MPO
rs2071409 minor C-allele group (AC/CC genotype) had a
higher prevalence of planned elective surgery (P¼ 0.002),
valve replacement (P¼ 0.02), and dialysis requirement
(P¼ 0.001), a higher median mechanical ventilation duration
(P¼ 0.007), and a higher postoperative day-1 mean APACHE
II score (P¼ 0.01) compared with the AA genotype group;
the MPO rs2759 minor C-allele group (TC/CC genotype)
had a prolonged mean CPB perfusion time (P¼ 0.05)
compared with the TT genotype group.
Association of MPO genotypes with plasma MPO and urinary
15-F2t-isoprostane levels
In the primary cohort, there was a strong genotype–pheno-
type association (Figure 1), as evidenced by the presence of
higher plasma MPO levels among the MPO rs2243828
(P¼ 0.02), rs7208693 (P¼ 0.01), rs2071409 (P¼ 0.003),
Table 1 | Observed and expected distribution of the four MPO gene polymorphisms in the primary and replication cohort
Allele frequencies Hardy–Weinberg equilibrium
Number of samples
successfully
genotyped
Primary
cohort
Secondary
cohort
Primary
cohort
Secondary
cohort
Locus
RefSNP number
(dbSNP) SNP Domain
Primary
cohort
Secondary
cohort Major Minor Major Minor v2 P-value v2 P-value
MPO rs2243828 765 T to C Promoter 260 277 T: 0.692 C: 0.308 T: 0.727 C: 0.273 0.22 0.64 0.23 0.63
MPO rs7208693 157 G to T Exon 2 (Val53Phe) 262 277 C: 0.874 A: 0.126 C: 0.884 A: 0.116 3.14 0.08 2.51 0.11
MPO rs2071409 9890 A to C Intron 11 260 275 A: 0.771 C: 0.229 A: 0.798 C: 0.202 1.41 0.23 2.02 0.16
MPO rs2759 2149 T to C Exon 12 (Ile717Val) 259 274 T: 0.932 C: 0.068 T: 0.923 C: 0.077 1.36 0.24 0.27 0.60
Abbreviations: db, database; MPO, myeloperoxidase; Ref, reference; SNP, single nucleotide polymorphism.
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and rs2759 (P¼ 0.03) minor-allele carriers. When the
heterozygous and homozygous minor-allele genotypes were
combined, the MPO rs2243825 (P¼ 0.04), rs7208693
(P¼ 0.001), rs2071409 (P¼ 0.02), and rs2759 (P¼ 0.03)
minor-allele carriers remained significantly associated with
higher plasma MPO levels (Table 2). To a lesser degree, there
was a similar but less robust association between higher
urinary 15-F2t-isoprostane levels and the MPO rs2243828
(P¼ 0.03), rs7208693 (P¼ 0.09), and rs2759 (P¼ 0.02)
minor-allele genotypes (Table 2).
In the secondary cohort, there was a similar but less global
genotype–phenotype association (Table 3), as evidenced by
higher preoperative plasma MPO levels among minor allele
genotype carriers for two of the four MPO polymorphisms,
rs7208693 (Po0.001) and rs2071409 (Po0.001).
Association of MPO gene polymorphisms and adverse
outcomes
For the primary cohort, the results of the multivariable
genetic dominant models are displayed in Table 4, showing a
Table 2 | Characteristics of the primary cohort according to the four MPO gene polymorphisms
rs2243828 genotype rs7208693 genotype rs2071409 genotype rs2759 genotype
Characteristic
TT
(n=123)
TC/CC
(n=137)
P-
value
GG
(n=197)
GT/TT
(n=65) P-value
AA
(n=158)
AC/CC
(n=102)
P-
value
TT
(n=224)
TC/CC
(n=35) P-value
Age, years 67 (16) 65 (15) 0.13 66 (16) 66 (14) 0.97 66 (16) 66 (15) 0.96 66 (16) 65 (15) 0.62
Men, % 54 52 0.77 56 43 0.07 55 49 0.34 53 49 0.62
Race, % 0.48 0.86 0.89 0.12
White 93 88 90 91 90 91 91 86
Black 5 9 7 8 8 6 6 14
Other 2 3 3 1 2 3 3 0
Contributing cause
of AKI, %
0.57 0.21 0.79 0.20
Ischemic 32 26 27 32 29 27 26 43
Nephrotoxic 15 17 16 14 17 14 17 9
Septic 4 7 9 11 9 10 10 3
Multifactorial/other 32 35 37 23 34 34 34 34
Comorbid conditions, %
Diabetes mellitus 44 45 0.92 46 39 0.28 48 39 0.19 47 26 0.02
Heart failure 16 16 0.96 17 12 0.35 17 16 0.87 17 14 0.74
Cirrhosis 5 10 0.16 5 14 0.02 6 10 0.22 6 17 0.02
Chronic lung disease 18 18 0.94 19 17 0.74 18 18 0.99 17 20 0.71
Chronic kidney
disease
73 65 0.17 71 60 0.13 66 71 0.43 69 58 0.19
APACHE II score 18 (5) 21 (7) 0.002 19 (6) 23 (7) o0.001 19 (6) 20 (6) 0.16 19 (6) 25 (7) o0.001
Sepsis, % 38 47 0.17 40 51 0.13 37 53 0.01 40 60 0.03
Shock, % 25 31 0.33 26 32 0.36 27 30 0.50 25 43 0.03
Serum creatinine, mg/dl
Baseline value 1.5 (0.6) 1.5 (0.8) 0.92 1.6 (0.7) 1.4 (0.6) 0.11 1.5 (0.6) 1.6 (0.9) 0.35 1.5 (0.7) 1.5 (0.6) 0.57
Enrollment value 3.5 (1.8) 3.6 (1.8) 0.89 3.6 (1.8) 3.5 (1.7) 0.88 3.5 (1.6) 3.7 (1.9) 0.40 3.5 (1.8) 3.7 (1.5) 0.64
Peak 4.3 (2.4) 4.4 (2.8) 0.63 4.2 (2.2) 4.7 (3.4) 0.24 4.2 (2.1) 4.6 (3.2) 0.22 4.4 (2.7) 4.2 (1.5) 0.77
Discharge 2.6 (1.9) 2.4 (1.4) 0.21 2.5 (1.8) 2.4 (1.4) 0.78 2.5 (1.8) 2.6 (1.5) 0.63 2.5 (1.8) 2.5 (1.2) 0.93
Urine output, l/day 1.4 (1.1) 1.1 (1.0) 0.05 1.3 (1.1) 1.1 (1.1) 0.10 1.4 (1.2) 1.1 (0.8) 0.02 1.4 (1.1) 0.7(0.7) o0.001
AKI stage at enrollment, % 0.23 0.02 0.68 0.06
Stage 1 49 38 48 28 45 41 46 26
Stage 2 4 5 4 6 5 4 4 8
Stage 3 47 57 48 66 50 55 50 66
Oxidative stress markers
Plasma nitrotyrosine,
nM
12 (9, 22) 12 (10, 22) 0.31 12 (9, 23) 12 (9, 23) 0.79 11 (9, 23) 12 (10, 23) 0.17 12 (9, 23) 12 (11, 32) 0.18
Plasma MPO, ng/ml 176 (103,
431)
248 (117,
674)
0.04 191 (105,
448)
421 (131,
1003)
0.001 188 (105,
444)
301 (115, 892) 0.02 207 (105,
501)
390 (170,
1208)
0.03
Urinary
15-F2t-isoprostane,
ng/mg
0.9 (0.5, 1.7) 1.3 (0.6, 2.7) 0.03 1.0 (0.6, 2.0) 1.7 (0.7, 2.8) 0.09 1.0 (0.5, 2.1) 1.4 (0.7, 2.3) 0.13 1.0 (0.5, 2.1) 1.8 (1.0, 2.8) 0.02
Abbreviations: AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; MPO, myeloperoxidase.
Continuous variables are presented as mean (s.d.) or median (25th and 75th percentile), and categorical variables as percentages.
Missing genotyping data on rs2243828 (n=2), rs2071409 (n=2), and rs2759 (n=3).
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robust association between the individual MPO polymorphic
minor alleles and the outcome of dialysis requirement or in-
hospital death, after adjustment for sex, race, and APACHE II
score. Compared with the TT genotype group, the MPO
rs2243828 C-allele group had an adjusted odds ratio (OR)
of 2.19 (95% confidence interval (CI) 1.25, 3.82) for this
composite outcome. A similar association was observed for
the MPO rs7208693 T-allele group compared with the GG
genotype group (adjusted OR 2.73; 95% CI 1.38, 5.38); the
MPO rs2071409 C-allele group compared with the AA
genotype (adjusted OR 2.09; 95% CI 1.18, 3.69); and the
MPO rs2759 C-allele group compared with the TT genotype
group (adjusted OR 3.15; 95% CI 1.22, 8.12). In all the
models, plasma MPO level was independently associated with
the 2 composite outcomes (Table 5), and after adding this
covariate to the models (model 3), the associations of the
MPO gene polymorphisms with the composite outcome
persisted but were attenuated (Table 4). Of note, in the
primary cohort, there was no association between urinary
15-F2t-isoprostane level and adverse outcomes (data not
shown). The associations between the individual MPO
polymorphic minor alleles and the composite of dialysis
requirement, assisted mechanical ventilation or in-hospital
death were less global, displaying significance on adjusted
analyses for two of the four (rs2243828 and rs7208693)
polymorphisms (Table 4).
Table 3 | Characteristics of the secondary cohort according to the four MPO gene polymorphisms
rs2243828
genotypes
rs7208693
genotypes
rs2071409
genotypes
rs2759
genotypes
Characteristic
TT
(n=145)
TC/CC
(n=132) P-value
GG
(n=214)
GT/TT
(n=63) P-value
AA
(n=179)
AC/CC
(n=96) P-value
TT
(n=233)
TC/CC
(n=41) P-value
Preoperative variables
Age, years 67 (12) 68 (11) 0.55 67 (11) 70 (12) 0.04 68 (12) 68 (11) 0.59 67 (12) 69 (11) 0.29
Men, % 77 67 0.09 73 70 0.63 73 71 0.68 74 61 0.08
White ethnicity, % 96 94 0.69 95 95 0.91 95 96 0.76 95 93 0.45
Hypertension, % 84 85 0.89 85 83 0.64 87 81 0.25 85 83 0.75
Diabetes mellitus, % 34 32 0.76 32 37 0.50 30 39 0.17 34 27 0.36
Heart failure, % 33 41 0.20 35 43 0.26 33 44 0.08 37 39 0.76
Chronic lung disease, % 28 33 0.36 30 30 0.99 28 34 0.29 28 44 0.16
Chronic kidney disease, % 18 27 0.15 21 32 0.22 21 25 0.53 22 27 0.59
Peripheral vascular disease, % 17 18 0.70 16 22 0.25 13 26 0.01 17 17 0.98
Cerebrovascular disease, % 11 11 0.93 11 11 0.98 11 12 0.94 12 7 0.38
3-Vessel coronary artery
disease, %
49 44 0.44 48 44 0.57 48 44 0.46 45 54 0.31
Left main coronary artery
disease, %
21 29 0.11 26 21 0.43 24 25 0.86 23 30 0.37
Serum creatinine, mg/dl 1.1 (1.0) 1.1 (0.4) 0.45 1.1 (0.9) 1.1 (0.3) 0.50 1.1 (0.9) 1.1 (0.3) 0.95 1.1 (0.8) 1.1 (0.3) 0.62
Plasma MPO, ng/ml 180
(87, 924)
180
(75, 949)
0.71 121
(74, 381)
1379
(802, 1721)
o0.001 115
(76, 527)
664
(124, 1513)
o0.001 179
(82, 834)
170
(67, 1213)
0.91
Operative variables
Elective surgery, % 26 37 0.06 28 43 0.03 25 43 0.002 29 43 0.09
Valve replacement, % 45 57 0.05 47 62 0.04 46 60 0.02 50 55 0.53
Aortic cross-clamp time, min 87 (40) 95 (43) 0.16 87 (37) 104 (52) 0.01 88 (39) 96 (45) 0.13 89 (41) 96 (45) 0.38
CPB perfusion time, min 113 (48) 124 (54) 0.07 111 (45) 142 (62) o0.001 111 (49) 131 (54) 0.002 115 (51) 132 (53) 0.05
Postoperative variables
Initial mechanical ventilation
duration, hours
13 (23) 25 (98) 0.14 16 (47) 30 (117) 0.16 11 (12) 34 (116) 0.007 15 (45) 43 (146) 0.02
Day-1 APACHE II score 13 (7) 14 (7) 0.22 12 (7) 18 (6) o0.001 13 (7) 15 (7) 0.01 13 (7) 14 (6) 0.54
Day-1 urine output, l/day 2.6 (1.0) 2.7 (1.0) 0.72 2.5 (1.0) 2.9 (1.0) 0.01 2.5 (1.0) 2.8 (1.1) 0.06 2.6 (1.0) 2.7 (1.3) 0.62
Stage 2 or 3 AKIa, % 2 3 0.58 3 0 0.51 1 5 0.07 2 7 0.05
Dialysis requirement, % 2 2 0.99 2 3 0.53 0 6 0.001 2 5 0.20
Abbreviations: AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; CPB, cardiopulmonary bypass; MPO, myeloperoxidase.
aMore than twofold increase in serum creatinine over the first three postoperative days.
Continuous variables are presented as mean (s.d.) or median (25th and 75th percentile values) and categorical variables as percentages.
Missing genotyping data on rs2071409 (n=2) and rs2759 (n=3).
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Figure 1 |Plasma levels of myeloperoxidase (MPO) in the
primary cohort stratified by the MPO genotypes. The data are
represented as median (25th and 75th percentile) values. The
P-values are derived from Wilcoxon signed-rank test.
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For the secondary cohort, the results of the multivariable
genetic dominant models are displayed in Table 6, showing a
strong association between two of the four MPO poly-
morphic minor alleles and the composite outcome of stage 2
AKI, dialysis requirement, prolonged mechanical ventilation
or in-hospital death, after adjustment for sex, race, age, heart
failure, surgery status, and CPB time. Indeed, compared with
the AA genotype group, the MPO rs2071409 C-allele group
had an adjusted OR of 2.82 (95% CI 1.22, 6.50) for this
composite outcome. A similar association was observed for
Table 4 | Association of the four MPO gene polymorphisms with adverse outcomes in the primary cohort
Dialysis requirement
or in-hospital death
Dialysis requirement,
mechanical ventilation, or in-hospital death
MPO gene polymorphism OR 95% CI P-value OR 95% CI P-value
Dominant model
rs2243828 (C-allele vs. T/T)
Unadjusted 2.53 1.53, 4.19 o0.001 2.31 1.40, 3.80 0.001
Model 1 2.65 1.59, 4.41 o0.001 2.37 1.43, 3.92 0.001
Model 2 2.19 1.25, 3.82 0.006 2.01 1.13, 3.57 0.017
Model 3 2.12 1.20, 3.75 0.010 1.98 1.10, 3.57 0.023
rs7208693 (T-allele vs. G/G)
Unadjusted 3.77 2.06, 6.92 o0.001 3.79 2.02, 7.13 o0.001
Model 1 4.04 2.18, 7.50 o0.001 3.91 2.07, 7.38 o0.001
Model 2 2.73 1.38, 5.38 0.004 2.52 1.22, 5.18 0.012
Model 3 2.66 1.31, 5.41 0.007 2.54 1.19, 5.41 0.016
rs2071409 (C-allele vs. A/A)
Unadjusted 2.07 1.25, 3.43 0.005 1.65 0.99, 2.73 0.053
Model 1 2.11 1.27, 3.51 0.004 1.65 0.99, 2.73 0.054
Model 2 2.09 1.18, 3.69 0.012 1.52 0.84, 2.73 0.164
Model 3 1.88 1.05, 3.38 0.035 1.34 0.73, 2.46 0.342
rs2759 (C-allele vs. T/T)
Unadjusted 5.63 2.36, 13.45 o0.001 5.48 2.19, 13.71 o0.001
Model 1 6.02 2.49, 14.55 o0.001 5.71 2.26, 14.40 o0.001
Model 2 3.15 1.22, 8.12 0.018 2.66 0.96, 7.37 0.059
Model 3 3.13 1.17, 8.40 0.024 2.68 0.93, 7.76 0.069
Additive model
rs2243828 (per C-allele copy increase)
Unadjusted 2.46 1.63, 3.72 o0.001 2.22 1.48, 3.35 o0.001
Model 1 2.54 1.67, 3.86 o0.001 2.25 1.49, 3.41 o0.001
Model 2 2.13 1.35, 3.37 0.001 1.92 1.20, 3.09 0.007
Model 3 2.07 1.29, 3.33 0.003 1.89 1.15, 3.09 0.012
rs7208693 (per T-allele copy increase)
Unadjusted 3.75 2.06, 6.85 o0.001 3.77 2.02, 7.05 o0.001
Model 1 4.02 2.17, 7.42 o0.001 3.88 2.06, 7.31 o0.001
Model 2 2.72 1.39, 5.35 0.004 2.51 1.22, 5.16 0.012
Model 3 2.66 1.31, 5.39 0.007 2.53 1.19, 5.39 0.016
rs2071409 (per C-allele copy increase)
Unadjusted 2.26 1.48, 3.45 o0.001 1.87 1.23, 2.85 0.003
Model 1 2.28 1.49, 3.50 o0.001 1.87 1.23, 2.85 0.004
Model 2 2.26 1.40, 3.64 0.001 1.77 1.09, 2.86 0.021
Model 3 2.07 1.27, 3.37 0.004 1.59 0.97, 2.62 0.067
T-G-A-T haplotypea
Unadjusted
1 Copy (vs. none) 0.15 0.05, 0.40 o0.001 0.18 0.07, 0.50 0.001
2 Copies (vs. none) 0.10 0.04, 0.30 o0.001 0.14 0.05, 0.41 o0.001
Model 1
1 Copy (vs. none) 0.15 0.05, 0.41 o0.001 0.18 0.07, 0.51 0.001
2 Copies (vs. none) 0.10 0.03, 0.29 o0.001 0.14 0.05, 0.40 o0.001
Model 2
1 Copy (vs. none) 0.16 0.06, 0.49 0.001 0.20 0.07, 0.62 0.005
2 Copies (vs. none) 0.13 0.04, 0.42 0.001 0.20 0.06, 0.63 0.006
Model 3
1 Copy (vs. none) 0.18 0.06, 0.55 0.003 0.22 0.07, 0.71 0.011
2 Copies (vs. none) 0.15 0.05, 0.50 0.002 0.23 0.07, 0.77 0.017
Abbreviations: CI, confidence interval; MPO, myeloperoxidase; OR, odds ratio.
aThe haplotype was generated from the MPO rs2243828, rs7208693, rs2071409, and rs2759 polymorphisms.
Model 1 is adjusted for sex, race, and age; model 2 is adjusted for sex, race, and APACHE II (Acute Physiology and Chronic Health Evaluation) score; model 3 is adjusted for sex,
race, APACHE II score, and plasma MPO level.
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the MPO rs2759 C-allele group compared with the TT
genotype group (adjusted OR 3.56; 95% CI 1.44, 8.82).
Notably, in the secondary cohort, there was no association
between the plasma MPO level and the composite outcome
(OR 0.89; 95% CI 0.62, 1.27; P¼ 0.514).
Sensitivity analyses
In sensitivity analyses performed in the primary cohort using
additive genetic models (Table 4), each copy of the MPO
rs2243828 C-allele, rs7208693 T-allele, and rs2071409 C-allele
was associated with 2.13- (95% CI 1.35, 3.37), 2.72- (95% CI
1.39, 5.35), and 2.26- (95% CI 1.40, 3.64) fold higher
adjusted odds for dialysis requirement or in-hospital death,
respectively. Using additive genetic models in the secondary
cohort, each copy of the MPO rs2071409 C-allele was
associated with 1.91-fold (95% CI 1.04, 3.51) higher adjusted
odds for the composite of stage 2 AKI, dialysis requirement,
prolonged mechanical ventilation, or in-hospital death
(Table 6).
Sensitivity analyses restricted to white subjects did not
affect any of the adjusted analyses in both the primary and
secondary cohort (see Supplementary Table S1 online).
Association of MPO haplotypes and adverse outcomes
We next generated a Haploview plot on the four MPO
polymorphisms. Figure 2 displays the linkage disequilibrium
(LD) plot at the MPO gene locus with representation of the
four variants analyzed in the primary cohort. The LD plot
revealed substantial marker-on-marker correlation (as de-
fined by the D parameter) across the B11 kbp human MPO
locus, with the rs2243828 and rs2759 polymorphisms
displaying the highest correlation, as evidenced by a D
parameter of 74, on a scale of 0–100.
We then conducted haplotype analyses. The most frequent
haplotype identified in the primary cohort across the four
MPO polymorphisms (rs2243828, rs7208693, rs2071409, and
rs2759) was T-G-A-T, which was estimated on 308 of the 524
chromosomes with a frequency of 59%, followed by C-G-A-T
(10%) and C-G-C-T (9%). As shown in Figure 3a, patients
with a higher copy-number of the T-G-A-T haplotype had
significantly lower plasma MPO levels (P¼ 0.002). This
association translated into a protective effect. Indeed, as
shown in Table 4, the presence of one copy or two copies of
the T-G-A-T haplotype was associated with a respective OR
of 0.16 (95% CI 0.06, 0.49) and 0.13 (95% CI 0.04, 0.42) for
the outcome of dialysis requirement on in-hospital, after
adjustment for sex, race, and APACHE II score. A similar
independent protective effect was observed for the composite
of dialysis requirement, assisted mechanical ventilation, or
in-hospital death (Table 4). In the secondary cohort, the most
frequent haplotype identified across the four MPO poly-
morphisms was also T-G-A-T, which was estimated on 330 of
the 554 chromosomes with a similar frequency of 60%,
followed by C-G-A-T (13%) and C-G-C-T (5%). A higher
copy-number of the T-G-A-T haplotype was also associated
with lower plasma MPO levels (Po0.001; Figure 3b), and a
similar but less global protective effect of the T-G-A-T
haplotype was observed (Table 6).
Using the single nucleotide polymorphism (SNP) Spectral
Decomposition method to account for multiple testing, the
experiment-wide significance threshold required to maintain
a type-1 error rate at o5% was 0.013, reflecting LD within
this block. In the primary cohort, this threshold (Po0.013)
was exceeded by markers rs2243828 and rs7208693 for the
outcome of dialysis requirement or in-hospital death in the
adjusted dominant-model analyses (model 3). The threshold
was also exceeded by markers rs2243828, rs7208693, and
rs2071409 in the adjusted additive-model analyses. Using this
method, the T-G-A-T haplotype also remained associated
with dialysis requirement or in-hospital death. The associa-
tion between the four MPO SNPs and the composite
outcome of dialysis requirement, assisted mechanical ventila-
tion, or in-hospital death became less robust after applying
this method. Similarly, in the secondary cohort, the only
marker that remained associated with the composite out-
come was rs2759 in the adjusted dominant-model analyses.
Table 5 | Association of plasma MPO levels with adverse clinical outcomes in the primary cohort
Outcome variable
Plasma log-MPO level
(per 1 s.d. increase) P-value C statistic
Dialysis requirement or in-hospital death
Unadjusted 1.96 (1.48, 2.58) o0.001 0.68
Adjusted for sex, race, APACHE II score, and rs2243828a 1.61 (1.18, 2.19) 0.002 0.79
Adjusted for sex, race, APACHE II score, and rs7208693a 1.61 (1.18, 2.20) 0.003 0.79
Adjusted for sex, race, APACHE II score, and rs2071409a 1.58 (1.16, 2.16) 0.004 0.79
Adjusted for sex, race, APACHE II score, and rs2759a 1.61 (1.18, 2.21) 0.003 0.79
Adjusted for sex, race, APACHE II score, and T-G-A-T haplotype 1.55 (1.13, 2.14) 0.007 0.80
Mechanical ventilation, dialysis requirement, or in-hospital death
Unadjusted 2.00 (1.51, 2.65) o0.001 0.68
Adjusted for sex, race, APACHE II score, and rs2243828a 1.62 (1.18, 2.23) 0.003 0.81
Adjusted for sex, race, APACHE II score, and rs7208693a 1.63 (1.17, 2.26) 0.004 0.82
Adjusted for sex, race, APACHE II score, and rs2071409a 1.60 (1.16, 2.22) 0.004 0.81
Adjusted for sex, race, APACHE II score, and rs2759a 1.67 (1.20, 2.31) 0.002 0.82
Adjusted for sex, race, APACHE II score, and T-G-A-T haplotype 1.57 (1.13, 2.19) 0.007 0.82
Abbreviation: MPO, myeloperoxidase.
aThe analysis refers to the dominant models.
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DISCUSSION
In the present two-step genetic study, we first examined the
relationship of four polymorphisms in the MPO gene locus
located in the promoter (rs2243828), coding (rs7208693
and rs2759), and non-coding (rs2071409) regions, with
plasma MPO and urinary 15-F2t-isoprostane levels, disease
severity measures, and adverse clinical outcomes in a
large cohort of hospitalized adults with a diagnosis of AKI,
which constituted our primary cohort. The observed and
expected genotype frequencies were not significantly differ-
ent, and fulfilled Hardy–Weinberg equilibrium. Minor allele
frequencies ranged from 7 to 31% for all four polymorph-
isms. The overall population was 91% white, and there were
no race, sex, or age differences within the genotype groups.
Strong genotype–phenotype associations were observed
between the four MPO gene polymorphisms and the two
selected markers of oxidative stress, plasma MPO (all four
SNPs) and urinary 15-F2t-isoprostane (SNPs rs2243828 and
rs2759) levels. All four polymorphisms were independently
associated with 2–3-fold higher odds for the composite
outcome of dialysis requirement or in-hospital death. A
similar but less robust association was observed for the
composite outcome of dialysis requirement, assisted mechan-
ical ventilation, or in-hospital death. Finally, we identified a
Table 6 | Association of the four MPO gene polymorphisms
with more than twofold increase in serum creatinine, dialysis
requirement, prolonged initial mechanical ventilation
(424h), or in-hospital death in the secondary cohort
MPO gene polymorphisms Odds ratio 95% CI P-value
Dominant model
rs2243828 (C-allele vs. T/T)
Unadjusted 1.38 0.68, 2.81 0.375
Model 1 1.27 0.55, 2.91 0.571
Model 2 1.20 0.52, 2.78 0.666
rs7208693 (T-allele vs. G/G)
Unadjusted 1.41 0.64, 3.12 0.395
Model 1 1.05 0.42, 2.62 0.911
Model 2 1.14 0.45, 2.87 0.780
rs2071409 (C-allele vs. A/A)
Unadjusted 2.90 1.41, 5.97 0.004
Model 1 2.86 1.24, 6.57 0.013
Model 2 2.82 1.22, 6.50 0.015
rs2759 (C-allele vs. T/T)
Unadjusted 3.29 1.46, 7.41 0.004
Model 1 3.50 1.42, 8.58 0.006
Model 2 3.56 1.44, 8.82 0.006
Additive model
rs2243828 (per C-allele copy increase)
Unadjusted 1.62 0.94, 2.78 0.082
Model 1 1.52 0.82, 2.81 0.179
Model 2 1.47 0.79, 2.74 0.227
rs7208693 (per T-allele copy increase)
Unadjusted 1.36 0.63, 2.94 0.438
Model 1 1.04 0.42. 2.54 0.939
Model 2 1.12 0.45, 2.80 0.801
rs2071409 (per C-allele copy increase)
Unadjusted 2.22 1.30, 3.78 0.003
Model 1 1.94 1.06, 3.57 0.033
Model 2 1.91 1.04, 3.51 0.037
T-G-A-T haplotypea
Unadjusted
1 Copy (vs. none) 0.37 0.15, 0.92 0.032
2 Copies (vs. none) 0.24 0.08, 0.71 0.010
Model 1
1 Copy (vs. none) 0.46 0.17, 1.27 0.134
2 Copies (vs. none) 0.30 0.08, 1.16 0.080
Model 2
1 Copy (vs. none) 0.49 0.18, 1.36 0.173
2 Copies (vs. none) 0.32 0.08, 1.28 0.108
Abbreviations: CI, confidence interval; MPO, myeloperoxidase.
aThe haplotype was generated from the MPO rs2243828, rs7208693, rs2071409, and
rs2759 polymorphisms.
Model 1 is adjusted for age, sex, race, and cardiopulmonary bypass time; model 2
is adjusted for age, sex, race, heart failure, surgery status, and cardiopulmonary
bypass time.
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Figure 2 |Haploview plot of the myeloperoxidase (MPO) gene
locus in the primary cohort. The plot illustrates pair-wise linkage
disequilibrium (LD) between the four MPO polymorphisms, based
on the D parameter value (scaled from 0 to 100). The darker the
rhombus appears, the higher the LD between the respective
polymorphisms.
1500
1000
P = 0.002 P0.001
0 (n
=
32
)
1 (n
=
15
1)
2 (n
=
78
)
2 (n
=
86
)
1 (n
=
15
8)
0 (n
=
33
)
500
Pl
as
m
a 
M
PO
 (n
g/m
l)
Pl
as
m
a 
M
PO
 (n
g/m
l)
0
1500
1000
500
0
Haplotype T-G-A-T
(number of copies)
Haplotype T-G-A-T
(number of copies)
Figure 3 |Plasma levels of myeloperoxidase (MPO). (a) The
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common haplotype (T-G-A-T) whereby the number of
copies was associated with lower plasma MPO level and
lower odds for adverse clinical outcomes. The results
remained robust across several sensitivity analyses, including
the use of additive models, restriction to white subjects only,
and correction for multiple testing using the SNP Spectral
Decomposition method. We next examined similar associa-
tions in a secondary cohort consisting of adults at risk for
AKI undergoing cardiac surgery with CPB, and observed a
significant though less global genotype–phenotype associa-
tion between two of the four MPO gene polymorphisms and
the outcome of stage 2 AKI, dialysis requirement, prolonged
mechanical ventilation, or in-hospital death.
MPO is an essential enzyme involved in oxidative
responses to a variety of stimuli. Following release from
neutrophils and monocytes through degranulation, MPO
reacts with hydrogen peroxide formed by the respiratory
burst to form a complex that can oxidize various compounds,
including chloride, which is oxidized to hypochlorous acid
leading to the formation of chlorine and chloramine. These
end-products are powerful oxidants that can exert biological
effects in the kidney.30 Indeed, in situ MPO activity has been
used as an index of neutrophil kidney parenchymal
infiltration in experimental models of ischemia-reperfusion
injury31–35 and nephrotoxicity.36,37
Given the importance of MPO in mediating oxidative
cellular injury in response to ischemic and toxic kidney
injury, one might anticipate that polymorphisms disrupting
or enhancing the function or expression of MPO would alter
oxidative stress–mediated cellular responses in AKI. Several
polymorphisms in the MPO gene locus have been described
and variably linked to measures of oxidative stress, including
rs7208693 (Val53Phe in exon-2 and examined in our study)
associated with higher MPO activity,38 and rs2333227
(located in the promoter region), associated with lower
MPO transcriptional activation.23
In the primary cohort, the potential mechanisms under-
lying the protective association of the common MPO T-G-A-
T haplotype with the composite endpoint of dialysis
requirement or in-hospital death are not completely under-
stood, but we propose that the improved outcomes observed
among carriers of this haplotype might, in part, be due to
lower generation or release of MPO from neutrophils,
resulting in less extensive organ injury. This hypothesis is
supported by the observed lower plasma MPO levels with a
higher copy-number of the T-G-A-T haplotype, which is
driven by the major rather than minor alleles of the
individual MPO SNPs.
To our knowledge, this is the first study to test the
hypothesis of whether representative polymorphisms across
the MPO gene locus associate with not only intermediate
phenotypes, i.e., plasma and urinary markers of oxidative
stress, but also adverse clinical outcomes in two separate
cohorts of adults with a diagnosis of AKI (primary cohort) as
well as adults at risk for AKI (secondary cohort). We used
overlapping composite outcome measures to allow meaningful
comparisons between the two cohorts. The demonstrable
MPO genotype–phenotype associations, whereby all four
polymorphic alleles were associated with higher plasma
MPO levels, strengthen the credibility of the observed
association between the various polymorphic alleles and
adverse outcomes. We also used clinically relevant covariates
in the multivariable models. These include the APACHE II
score in the primary cohort, which captures severity of the
acute illness, and heart failure, surgery status, and CPB time in
the secondary cohort, which capture known risk factors for
post-cardiac surgery AKI. Our composite outcomes included
in-hospital death, which accounted for survival bias when
assessing endpoints of artificial organ support (i.e., dialysis
requirement or assisted/prolonged mechanical ventilation).
Finally, the results observed on the secondary cohort support
and validate our primary findings.
There are several study limitations that should be noted.
The heterogeneity of the primary cohort was offset by the
selective inclusion of subjects with more advanced stages of
AKI requiring nephrology consultation. Although the two
cohorts were relatively small for genetic epidemiological
analyses, there was no deviation from expected genotype
frequencies, and the B91–95% majority of white subjects
likely minimized the potential influence of race on genotype
frequencies. Although the observed genetic associations might
reflect some degree of genetic admixture, the association of
higher plasma MPO level with increased odds for adverse
outcomes in the primary cohort argues for the suitability
of this oxidative stress marker as a downstream effector
of polymorphisms in the MPO gene locus. The attenuation of
the point estimates in the genetic markers after adding plasma
MPO levels to the multivariable models supports this
hypothesis. Multiple testing, which is an important limitation
of the analysis, was addressed by applying the SNP Spectral
Decomposition method to derive stricter P-values to define
significance. Finally, within the associated MPO haplotype
block, several potentially functional genetic variants lie, but
the biological mechanism by which MPO haplotypes might
influence renal traits remains uncertain.
In conclusion, in the present two-step genetic study, we
provide evidence that four polymorphisms in the MPO gene
locus and a common corresponding haplotype influence the
risk of adverse outcomes in hospitalized adults with or at risk
for AKI. Although this effect seems to be mediated by
modulation of the extracellular release of MPO, additional
studies are needed to establish the mechanisms underlying
the influence of the identified genotypes on disease traits.
MATERIALS AND METHODS
Study design and participants
The primary cohort was derived from a prospective cohort study
conducted at two acute care hospitals where adults with AKI, in
whom nephrology consultation was requested, were eligible for
enrollment. AKI was defined as a rise in serum creatinine by 0.5, 1.0,
or 1.5mg/dl from a baseline level of p1.9, 2.0–4.9, or X5.0mg/dl,
respectively.39 Although this definition was adopted before the
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development of the AKI network consensus definition,40 we used
this classification to categorize the stages of AKI. Exclusion criteria
were age o18 years, pregnancy, chronic dialysis, organ transplanta-
tion within the previous year, and urinary obstruction.
The secondary cohort was derived from a prospective cohort
study of patients at risk for AKI following cardiac surgery,
conducted at four acute care hospitals, where adults scheduled to
undergo on-pump cardiac surgery were eligible for enrollment.
Exclusion criteria were ageo18 years, off-pump surgery, pregnancy,
acute or chronic dialysis dependence, and organ transplantation
within the previous year.
Institutional review board approval was granted, and written
informed consent was obtained from all the participants or next of kin.
Data collection
Data collection for the primary cohort included baseline demo-
graphic characteristics, comorbid conditions, 24-h urine output at
enrollment, and serial serum creatinine values. Sepsis was ascer-
tained using the systemic inflammatory response syndrome
criteria,41 and two severity-of-illness scores were calculated, the
APACHE II score42 and the Multiple Organ Failure score.43 Pre-
existing chronic kidney disease was defined on the basis of a baseline
estimated glomerular filtration rate of o60ml/min per 1.73m2,
which was calculated using the Modification of Diet in Renal Disease
study equation.44
Data collection for the secondary cohort included baseline
demographic characteristics, preoperative comorbid conditions and
laboratory variables, intraoperative variables (surgery electivity and
type, CPB perfusion time, and aortic cross-clamp time), and several
postoperative variables, including day-1 APACHE II score and urine
output, initial hours of assisted mechanical ventilation, and serial
serum creatinine values over the first 3 days.
Blood and urine sampling
At enrollment, EDTA-anticoagulated whole blood and urine were
collected. Plasma was separated, and the remaining blood was aliquoted
for subsequent DNA extraction. Urine samples were obtained from a
fresh void or the access port of a Foley catheter, kept on ice, centrifuged
(within 30min) for 10min at 3000 r.p.m., treated with a protease
inhibitor cocktail (Complete Mini, Roche Diagnostics, Mannheim,
Germany), aliquoted in cryotubes, and stored at 801C.
Selection criteria for genetic variants
To obtain comprehensive representation of the genetic variability in
the MPO gene locus (reference sequence GeneBank accession
number, NM 000250.1), we selected tag-SNPs using the HapMap
genome browser for European populations (http://hapmap.
ncbi.nlm.nih.gov/) with the tagger pair-wise method, a r2 cutoff of
0.8, and a minor allele frequency of at least 10%. These genetic
variants were also selected on the basis of published reports on
investigated clinical and functional associations. Through this
selection process, we identified four MPO polymorphisms of
interest spanning the gene (50–30 direction) (Table 1), located in
the promoter (765 T to C, RefSNP rs2243828), exon 2 (þ 157 G to
T, RefSNP rs7208693), intron 11 (þ 9890 A to C, RefSNP
rs2071409), and exon 12 (þ 2149 T to C, Ile717Val, RefSNP rs2759).
TaqMan genotyping and haplotype analyses
Genomic DNAwas prepared from whole-blood leukocytes using the
QiAmp DNA blood kit (Qiagen, Valencia, CA). Using the Applied
Biosystems 7900HT fast real-time PCR system (Applied Biosystems,
Foster City, CA), DNA samples were genotyped by combining the
TaqMan universal PCR master mix with TaqMan SNP genotyping
assay into a 384-well plate according to a standardized protocol.
Resulting sequences were analyzed by the SNP software (Applied
Biosystems, SDS version 2.2), which utilizes an advanced multi-
component algorithm to calculate distinct allele/marker signal
contributions from fluorescence measurements for each sample well
during the assay plate read with the SNP auto-caller. The SNP auto-
caller automatically determines sample genotypes and generates a
cluster plot to better visualize data across samples.
Pair-wise patterns of LD across the MPO gene locus were
visualized by Haploview, plotting LD as the D parameter (scaled
from 0 to 100). Haplotypes were imputed from the MPO
polymorphism diploid genotypes using PLINK version 1.07, a
toolset for whole-genome association and population-based linkage
analysis45 (http://pngu.mgh.harvard.edu/~purcell/plink/). The most
frequent haplotype (T-G-A-T) identified across the four (50–30
direction) MPO polymorphisms (rs2243828, rs7208693, rs2071409,
and rs2759) was expressed as the number of chromosomal copies (0,
1, or 2 haplotypes) per diploid individual.
Measurement of markers of oxidative stress
To evaluate whether the MPO gene polymorphisms were associated
with markers of oxidative stress, we measured plasma levels of MPO,
the MPO gene product, and urinary levels of 15-F2t-isoprostane,
a marker of lipid peroxidation. Plasma MPO was measured by
solid-phase enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN), results reported as ng/ml. The intra- and inter-
assay coefficient of variations are 7.3 and 8.1%, respectively. Urinary
15-F2t-isoprostane was measured by competitive enzyme-linked
immunosorbent assay (Northwest Life Science Specialties, LLC,
Vancouver, WA), results were normalized to urinary creatinine and
expressed as ng/mg of creatinine. The intra- and inter-assay
coefficient of variations are 5 and 10%, respectively. All measure-
ments were performed in duplicate.
Outcome measures
In the primary cohort, the main outcomes of interest were the
composite of dialysis requirement or in-hospital death as well as
dialysis requirement, assisted mechanical ventilation, or in-hospital
death. In the secondary cohort, the main outcome measure was the
composite of stage 2 or 3 AKI according to the AKI network
consensus definition (more than twofold increase in serum
creatinine over the first 3 postoperative days),40 dialysis require-
ment, prolonged (424 h) mechanical ventilation according to the
definition by the Society of Thoracic Surgeons, (http://www.sts.org/
sites/default/files/documents/pdf/trainingmanuals/Tab15-SectionO-
POSTOPERATIVE.pdf) or in-hospital death.
Statistical analyses
The genotype frequencies were tested for Hardy–Weinberg
equilibrium using a standard w2 test for any deviation of the
observed frequencies. Comparisons between genotype groups
were made by the t-test and the two-tailed Mann–Whitney test
for continuous variables, and by w2 or Fisher’s exact test for
categorical variables. Continuous variables are reported as mean
(with s.d.) or median (with 25th and 75th percentile) according to
their distribution. Binary variables are reported as count (with
percentage).
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Multivariable logistic regression analyses were performed to
examine the association of each MPO gene polymorphism with the
aforementioned outcomes, using dominant genetic models (i.e., one
or two copies of the minor allele). In the primary cohort, the models
were adjusted for sex, race, and age (model 1); sex, race, and
APACHE II score (model 2); or sex, race, APACHE II score, and log-
transformed plasma MPO level (model 3). In the secondary cohort,
the models were adjusted for sex, race, and age (model 1); or sex,
race, age, heart failure, surgery status, and CPB time (model 2).
Similar multivariable logistic regression analyses were performed
for the association of the MPO T-G-A-T, haplotype and the
outcomes of interest. Several sensitivity analyses were performed,
including the use of additive genetic models and restriction of the
cohort to white subjects only. The SNP Spectral Decomposition
method46 was used to correct for multiple testing for SNPs that were
in LD with each other, on the basis of the spectral decomposition of
matrices of pair-wise LD between SNPs displayed in the Haploview
plot of the MPO gene locus (Figure 2). In brief, this method
estimates within a haplotype block, the experiment-wide signifi-
cance threshold required to maintain the type-1 error rate at 5%.
The results of the logistic regression analyses are displayed as ORs
with 95% CI. All statistical analyses were performed using the SAS
software (version 9.2, SAS Institute, Cary, NC). Differences were
considered statistically significant at a P-value of o0.05.
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